NASDAQ
Tango Therapeutics, Inc. (TNGX)
♥ 654 Thanks from members
Tango Therapeutics, Inc. (TNGX) exhibits strong Wall Street bullishness anchored by promising vopimetostat pancreatic cancer data and major price target hikes, contrasted with retail uncertainty, an earnings miss, zero collaboration revenue, and a $400 million ATM offering.